Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas
- 1 January 1993
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 8 (4) , 306-311
- https://doi.org/10.1002/mc.2940080414
Abstract
Esophageal carcinomas from 24 patients, most of whom were smokers and consumed alcoholic beverages daily, were analyzed for mutations in exons 5–8 of the p53 tumor suppressor gene. Mutations were identified by polymerase chain reaction amplification and direct sequencing in 12 of 24 (50%) of the samples; almost half of the mutations were at A:T base pairs. Nuclear accumulation of p53 protein, determined by immunohisto‐chemistry with the CM‐1 polyclonal antibody, was observed in all cases in which a missense mutation in the p53 gene was detected. None of the 24 carcinomas had amplification of the mdm2 gene, an alternate pathway to p53 loss of function. Alterations involving three other cancer‐related genes associated with human esophageal carcinogenesis, c‐erbB‐1/epidermal growth factor receptor (EGFR), c‐myc, and retinoblastoma (Rb), were examined by Southern blot or immunohistochemical analysis in the same sample set to explore the possibility of a link between oncogene activation and loss of tumor suppressor function. While no associations were observed between amplification of the c‐myc or EGFR genes and p53 abnormalities, a significant correlation (P < 0.01) was seen between the presence of p53 mutation and EGFR overexpression. Absence of Rb protein, measured immunohistochemically, was observed in four tumors, none of which had aberrations of the p53 gene.Keywords
This publication has 24 references indexed in Scilit:
- Abrogation by c-myc of Gl phase arrest induced by RB protein but not by p53Nature, 1992
- Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53Published by Elsevier ,1992
- Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 allelesCell, 1992
- ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutationCell, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- p53 Mutations in Human CancersScience, 1991
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989
- Amplification of the EGF receptor and c‐myc genes in human esophageal cancersInternational Journal of Cancer, 1988
- The Molecular Genetics of CancerScience, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987